Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

Not Applicable

• Conditions: Breast Cancer
• Interventions: Drug: Capecitabine

• Registration Number: NCT02028494
• Lead Sponsor: Latin American & Caribbean Society of Medical Oncology

Brief Summary

The purpose of this study is to compare the efficacy of a novel schedule of an oral anticancer drug, capecitabine, in patients with metastatic breast cancer.

Mathematical models have predicted that 7 days of capecitabine followed by 7 days of rest is an optimal dosing schedule for this drug and previous studies done al Memorial Sloan Kettering Cancer Center support the tolerability of this scheme.

This definitive, randomized trial comparing the efficacy of the new dosage with the conventional dosing schedule in patients with metastatic breast cancer is necessary and we hypothesize it will be superior in terms of efficacy.

Dosing schedules based on mathematical predictions for optimal drug delivery based on efficacy rather than toxicity could facilitate more rapid and economical drug development. This trial is a proof of principle trial of the highest priority.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08
• Study First Submitted: 2014-01-03
• Study First Submitted QC: 2014-01-03
• Study First Posted: 2014-01-07
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-06
• Last Update Posted: 2018-09-07
• Primary Completion: 2018-12
• Study Completion: 2019-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 350

Inclusion Criteria

• 1 Subject Inclusion Criteria

  • Informed consent has been obtained.

  • Metastatic breast cancer.

  • Measurable or non-measurable disease per RECIST criteria.

  • Pathologic confirmation of breast cancer.

  • No limit to the number of prior chemotherapy regimens permitted for metastatic disease.

  • At least 3 weeks since prior chemotherapy. Patients should have recovered from all acute toxicity from such therapy (excluding alopecia).

  • Age ≥18.

  • ECOG 0-2

  • Absolute Neutrophil Count (ANC )≥1.0; hemoglobin ≥9, platelets

    ≥75.000

  • AST, ALT and Alkaline phosphatase <2.5x upper limit of normal (or <5x upper limit of normal in the case of liver metastases). Total bilirubin <1.5x upper limit of normal.

  • Estimated creatinine clearance >50ml/min.

  • If female of childbearing potential, pregnancy test is negative and the patient agrees to use an effective method to avoid pregnancy during the study.

Read More

Exclusion Criteria

• HER2 over-expression and/or amplification as determined by immunohistochemistry (3+) or FISH (>2.0).

  • No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if >12 months have elapsed since treatment.
  • No restriction for prior hormonal therapy.
  • GI malabsorption syndrome which could impair oral drug absorption.
  • Concurrent use of warfarin is discouraged as drug interactions may make management of INR more difficult.
  • Central nervous system metastases are permitted if previously treated or clinically stable for at least 3 months.
  • Pregnant or nursing patients.
  • Life expectancy <3 months.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day	Capecitabine	Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
Arm A: Capecitabine 2,000 mg (flat dose)	Capecitabine	Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).

Primary Outcome Measures

Name	Time	Method
Progress Free Survival (PFS)	24 month	The primary endpoint of this study is PFS, defined as the time from treatment start to progression or last date of follow-up. PFS will be estimated using Kaplan-Meier methods. This will be an intention to treat analysis. The Log-rank test will be used to test whether PFS is different for the two capecitabine schedules. It is hypothesized that the 7-7 schedule of capecitabine will have superior efficacy.

Secondary Outcome Measures

Name	Time	Method
Number of patients with study withdrawal.	24 month
Number of participants with toxicity.	24 month	Secondary Objectives: * To assess and compare tolerability of the two capecitabine schedules in terms of selected hematologic and non-hematologic toxicities.; * To compare the rates of grade 3 or greater diarrhea, nausea and vomiting between the two schedules.
Number of patients with treatment delays.	24 month
Number of patients with dose reduction.	24 month

Trial Locations

Locations (1)

SLACOM; 🇦🇷 Buenos Aires, Argentina